检索范围:
排序: 展示方式:
Intracellular and extracellular TGF-β signaling in cancer: some recent topics
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 387-411 doi: 10.1007/s11684-018-0646-8
Transforming growth factor (TGF)-β regulates a wide variety of cellular responses, including cell growth arrest, apoptosis, cell differentiation, motility, invasion, extracellular matrix production, tissue fibrosis, angiogenesis, and immune function. Although tumor-suppressive roles of TGF-β have been extensively studied and well-characterized in many cancers, especially at early stages, accumulating evidence has revealed the critical roles of TGF-β as a pro-tumorigenic factor in various types of cancer. This review will focus on recent findings regarding epithelial-mesenchymal transition (EMT) induced by TGF-β, in relation to crosstalk with some other signaling pathways, and the roles of TGF-β in lung and pancreatic cancers, in which TGF-β has been shown to be involved in cancer progression. Recent findings also strongly suggested that targeting TGF-β signaling using specific inhibitors may be useful for the treatment of some cancers. TGF-β plays a pivotal role in the differentiation and function of regulatory T cells (Tregs). TGF-β is produced as latent high molecular weight complexes, and the latent TGF-β complex expressed on the surface of Tregs contains glycoprotein A repetitions predominant (GARP, also known as leucine-rich repeat containing 32 or LRRC32). Inhibition of the TGF-β activities through regulation of the latent TGF-β complex activation will be discussed.
关键词: TGF-β EMT lung cancer pancreatic cancer latent form immune function GARP
Advances on immune-related adverse events associated with immune checkpoint inhibitors
Yong Fan, Yan Geng, Lin Shen, Zhuoli Zhang
《医学前沿(英文)》 2021年 第15卷 第1期 页码 33-42 doi: 10.1007/s11684-019-0735-3
关键词: cancer immunotherapy immune checkpoint inhibitors immune-related adverse events review
Natural killer cells in liver diseases
null
《医学前沿(英文)》 2018年 第12卷 第3期 页码 269-279 doi: 10.1007/s11684-018-0621-4
The liver has been characterized as a frontline lymphoid organ with complex immunological features such as liver immunity and liver tolerance. Liver tolerance plays an important role in liver diseases including acute inflammation, chronic infection, autoimmune disease, and tumors. The liver contains a large proportion of natural killer (NK) cells, which exhibit heterogeneity in phenotypic and functional characteristics. NK cell activation, well known for its role in the immune surveillance against tumor and pathogen-infected cells, depends on the balance between numerous activating and inhibitory signals. In addition to the innate direct “killer” functions, NK cell activity contributes to regulate innate and adaptive immunity (helper or regulator). Under the setting of liver diseases, NK cells are of great importance for stimulating or inhibiting immune responses, leading to either immune activation or immune tolerance. Here, we focus on the relationship between NK cell biology, such as their phenotypic features and functional diversity, and liver diseases.
关键词: natural killer cell phenotype immune activation immune tolerance liver diseases
Tangchun Wu
《医学前沿(英文)》 2020年 第14卷 第6期 页码 816-819 doi: 10.1007/s11684-020-0823-4
Heterogeneity of the tumor immune microenvironment and clinical interventions
《医学前沿(英文)》 2023年 第17卷 第4期 页码 617-648 doi: 10.1007/s11684-023-1015-9
Molecular classification and precision therapy of cancer: immune checkpoint inhibitors
null
《医学前沿(英文)》 2018年 第12卷 第2期 页码 229-235 doi: 10.1007/s11684-017-0581-0
On May 23, 2017, the US Food and Drug Administration (FDA) approved a treatment for cancer patients with positive microsatellite instability-high (MSI-H) markers or mismatch repair deficient (dMMR) markers. This approach is the first approved tumor treatment using a common biomarker rather than specified tumor locations in the body. FDA previously approved Keytruda for treatment of several types of malignancies, such as metastatic melanoma, metastatic non-small-cell lung cancer, recurrent or metastatic head and neck cancer, refractory Hodgkin lymphoma, and urothelial carcinoma, all of which carry positive programmed death-1/programmed death-ligand 1 biomarkers. Therefore, indications of Keytruda significantly expanded. Several types of malignancies are disclosed by MSI-H status due to dMMR and characterized by increased neoantigen load, which elicits intense host immune response in tumor microenvironment, including portions of colorectal and gastric carcinomas. Currently, biomarker-based patient selection remains a challenge. Pathologists play important roles in evaluating histology and biomarker results and establishing detection methods. Taking gastric cancer as an example, its molecular classification is built on genome abnormalities, but it lacks acceptable clinical characteristics. Pathologists are expected to act as “genetic interpreters” or “genetic translators” and build a link between molecular subtypes with tumor histological features. Subsequently, by using their findings, oncologists will carry out targeted therapy based on molecular classification.
关键词: molecular classification precision medicine pembrolizumab PD-1/PD-L1 MSI-H
null
《医学前沿(英文)》 2014年 第8卷 第1期 页码 1-5 doi: 10.1007/s11684-014-0309-3
Hyperthermia is a condition characterized by increased body temperature as a consequence of failed thermoregulation. Hyperthermia occurs when a body produces or absorbs more heat than it dissipates. Hyperthermia also elicits various effects on the physiology of living cells. For instance, fever-range temperature (39β°C to 40β°C) can modulate the activities of immune cells, including antigen-presenting cells, T cells, and natural killer cells. Heat shock temperature (41β°C to 43β°C) can increase the immunogenicity of tumor cells. Cytotoxic temperature (>43β°C) can create an antigen source to induce an anti-tumor immune response. The immunomodulatory effect of hyperthermia has promoted an interest in hyperthermia-aided immunotherapy, particularly against tumors. Hyperthermia has also been used to treat deep fungal, bacterial, and viral skin infections. We conducted a series of open or controlled trials to treat skin human papillomavirus infection by inducing local hyperthermia. More than half of the patients were significantly cured compared with those in the control trial. A series of challenging clinical cases, such as large lesions in pregnant patients or patients with diabetes mellitus, were also successfully and safely managed using the proposed method. However, further studies should be conducted to clarify the underlying mechanisms and promote the clinical applications of hyperthermia.
SARS-CoV-2 variants, immune escape, and countermeasures
《医学前沿(英文)》 2022年 第16卷 第2期 页码 196-207 doi: 10.1007/s11684-021-0906-x
关键词: SARS-CoV-2 COVID-19 vaccine immune escape breakthrough prevention
Multi-target combinatory strategy to overcome tumor immune escape
《医学前沿(英文)》 2022年 第16卷 第2期 页码 208-215 doi: 10.1007/s11684-022-0922-5
关键词: immune checkpoints multi-target immune escape immune-related adverse events combination therapy
《医学前沿(英文)》 2022年 第16卷 第5期 页码 773-783 doi: 10.1007/s11684-021-0902-1
关键词: benefit China eligibility immune checkpoint inhibitor public health
Innate immune responses in RNA viral infection
Qian Xu, Yuting Tang, Gang Huang
《医学前沿(英文)》 2021年 第15卷 第3期 页码 333-346 doi: 10.1007/s11684-020-0776-7
关键词: innate immune viral infection intercellular signaling metabolic changes epigenetic changes
Zhen Xiang, Yingyan Yu
《医学前沿(英文)》 2019年 第13卷 第1期 页码 24-31 doi: 10.1007/s11684-019-0679-7
关键词: immune checkpoint blockade sensitivity resistance data mining
《医学前沿(英文)》 2022年 第16卷 第4期 页码 596-609 doi: 10.1007/s11684-021-0868-z
关键词: innate immune checkpoint Siglec10 kidney renal clear cell carcinoma
标题 作者 时间 类型 操作
Advances on immune-related adverse events associated with immune checkpoint inhibitors
Yong Fan, Yan Geng, Lin Shen, Zhuoli Zhang
期刊论文
Persistence of humoral and cellular immune response after SARS-CoV-2 infection: opportunities and challenges
Tangchun Wu
期刊论文
Hyperthermia on skin immune system and its application in the treatment of human papillomavirus-infected
null
期刊论文
Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors
期刊论文
Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases
Zhen Xiang, Yingyan Yu
期刊论文
Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient
期刊论文